Page last updated: 2024-09-04

cinacalcet and Cardiovascular Diseases

cinacalcet has been researched along with Cardiovascular Diseases in 55 studies

Research

Studies (55)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	9 (16.36)	29.6817
2010's	41 (74.55)	24.3611
2020's	5 (9.09)	2.80

Authors

Authors	Studies
Chertow, GM; Floege, J; Liu, S; Nilsson, E; Stedman, MR; Stenvinkel, P	1
Bacchetta, J; Bernardor, J; De Mul, A; Schmitt, CP	1
Evenepoel, P; Jørgensen, HS	1
Ayach, T; El-Husseini, A; Elyamny, M; Kakani, E	1
Li, H; Lu, X; Song, J; Wang, S; Yu, L; Zu, Y	1
Bures, C; Dobrindt, EM; Mogl, MT; Pratschke, J; Rayes, N; Reinke, P; Skachko, T	1
Johnson, DW; Mavridis, D; Palmer, SC; Ruospo, M; Strippoli, GFM; Tonelli, M	1
Friedl, C; Kramar, R; Mann, JFE; Pilz, S; Reibnegger, G; Rosenkranz, AR; Zitt, E	1
Sin, HY	1
Barany, P; Birnie, K; Carrero, JJ; Caskey, FJ; Evans, M; Gasparini, A; MacNeill, S; May, MT; Methven, S	1
Hamano, T; Lim, K; Thadhani, R	1
Chertow, GM; Decker, BS; Edenberg, HJ; Foroud, TM; Long, J; Moe, SM; Schwantes-An, TL; Vatta, M; Wetherill, L; Xuei, X	1
Criseno, S; Gittoes, NJL; Hassan-Smith, ZK	1
Chertow, GM; Franchetti, Y; Liu, S; Long, J; Mahnken, JD; Nolin, TD; Prokopienko, AJ; Stedman, MR; Stubbs, JR; West, RE	1
Bhargava, R; Brenchley, P; Hann, M; Hurst, H; Hutchison, AJ; Kalra, PA	1
Covic, A; Craig, JC; Messa, P; Nistor, I; Palmer, SC; Pellegrini, F; Strippoli, GF; Tonelli, M	1
Cavalier, E; Delanaye, P; Krzesinski, JM	1
Charytan, C; Yousaf, F	1
Moe, SM; Thadhani, R	1
Adema, AY; de Borst, MH; Ter Wee, PM; Vervloet, MG	1
Covic, A; Goldsmith, D	1
Ballinger, AE; Craig, JC; Nistor, I; Palmer, SC; Strippoli, GF	1
Block, GA; Chertow, GM; Correa-Rotter, R; Dehmel, B; Drüeke, TB; Floege, J; Goodman, WG; Herzog, CA; Kubo, Y; London, GM; Mahaffey, KW; Moe, SM; Parfrey, PS; Wheeler, DC	1
Battista, M; Cena, T; Fenoglio, R; Lazzarich, E; Musetti, C; Quaglia, M; Stratta, P	1
Yokoyama, K	1
Abdalla, S; Block, GA; Chang, TI; Chertow, GM; Correa-Rotter, R; Dehmel, B; Drüeke, TB; Floege, J; Goodman, WG; Herzog, CA; London, GM; Mahaffey, KW; Moe, SM; Parfrey, PS; Wheeler, DC	1
Block, GA; Chertow, GM; Correa-Rotter, R; Dehmel, B; Drüeke, TB; Floege, J; Goodman, WG; Herzog, CA; Kubo, Y; London, GM; Mahaffey, KW; Moe, SM; Parfrey, PS; Stolina, M; Wheeler, DC	1
Abdalla, S; Block, GA; Chertow, GM; Correa-Rotter, R; Dehmel, B; Drüeke, TB; Floege, J; Goodman, WG; Herzog, CA; London, GM; Mahaffey, KW; Middleton, JP; Moe, SM; Parfrey, PS; Pun, PH; Wheeler, DC	1
Block, GA; Chertow, GM; Correa-Rotter, R; Drüeke, TB; Floege, J; Herzog, CA; London, GM; Mahaffey, KW; Moe, SM; Parfrey, PS; Wheeler, DC	1
Ito, T; Iwashita, Y; Shigematsu, T	1
Belozeroff, V; Briggs, AH; Chertow, GM; Dehmel, B; Khan, N; Kubo, Y; Parfrey, PS; Tseng, S	1
Agarwal, A; Busse, JW; Guyatt, GH; Lopes, LC; Mustafa, RA; Sekercioglu, MF; Sekercioglu, N; Shaikh, S; Thabane, L	1
Arampatzis, S; Bachtler, M; Block, GA; Chertow, GM; Floege, J; Jahnen-Dechent, W; Ma, X; Parfrey, P; Pasch, A; Smith, ER	1
Sane, DC	1
Al-Aly, Z	1
Block, GA; Brillhart, S; Liu, J; Nieman, K; Persky, M; Smits, G; St Peter, WL; Zaun, D	1
Evans, M; Fored, CM	1
Klein, GL	1
Bonomini, M; Brancaccio, D; Cancarini, G; Cannella, G; Caruso, MR; Cascone, C; Costanzo, AM; Cozzolino, M; di Luzio Paparatti, U; Mazzaferro, S; Messa, P	1
Borrajo Prol, M; Camba Caride, M; Conde Rivera, O; Iglesias Lamas, E; López Alarcóon, W; Novoa Fernández, E; Santos Nores, J	1
Karohl, C; Raggi, P	1
Block, GA; Chertow, GM; Correa-Rotter, R; Drueke, TB; Floege, J; Goodman, WG; Herzog, CA; Kubo, Y; London, GM; Mahaffey, KW; Mix, TC; Moe, SM; Parfrey, PS; Wheeler, DC	1
Hu, B; Hu, P; Lu, L; Qin, YH; Wang, J; Xuan, Q	1
Bian, A; Ellis, CD; Hung, AM; Ikizler, TA; Plotnikova, NE; Shintani, A; Siew, ED; Sundell, MB	1
Goldsmith, D; Leonard, O; Spaak, J	1
Neal, B; Perkovic, V	1
Block, GA; Chertow, GM; Correa-Rotter, R; Drüeke, TB; Floege, J; Goodman, WG; Herzog, CA; Kubo, Y; London, GM; Mahaffey, KW; Mix, TC; Moe, SM; Parfrey, PS; Trotman, ML; Wheeler, DC	1
Chudek, J; Kocełak, P; Olszanecka Glinianowicz, M; Zelaźnicka, M	1
Chertow, GM; Cunningham, J; Danese, M; Klassen, P; Olson, K	1
Anders, HJ	1
Bilezikian, JP; Silverberg, SJ	1
Anderson, R; D'Souza, R; Garside, R; Mealing, S; Pitt, M; Roome, C; Snaith, A; Stein, K; Welch, K	1
Joy, MS; Karagiannis, PC; Peyerl, FW	1
Albizem, M; Block, GA; Chertow, GM; Correa-Rotter, R; Drueke, TB; Floege, J; Goodman, WG; Klassen, P; London, GM; Mahaffey, KW; Moe, SM; Olson, K; Parfrey, P; Pupim, LB; Wheeler, DC	1
Akizawa, T; Kinugasa, E; Koiwa, F; Ogata, H	1

Reviews

26 review(s) available for cinacalcet and Cardiovascular Diseases

Article	Year
Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients. Current osteoporosis reports, 2023, Volume: 21, Issue:2 Topics: Adult; Calcimimetic Agents; Calcium; Cardiovascular Diseases; Child; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Minerals; Parathyroid Hormone; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Vitamin D	2023
Pathogenesis and management of vascular calcification in CKD and dialysis patients. Seminars in dialysis, 2019, Volume: 32, Issue:6 Topics: Calciphylaxis; Calcitriol; Cardiovascular Diseases; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Comorbidity; Female; Humans; Incidence; Kidney Failure, Chronic; Male; Prognosis; Renal Dialysis; Risk Assessment; Severity of Illness Index; Treatment Outcome; Vascular Calcification; Vitamin D	2019
Cinacalcet Treatment Significantly Improves All-Cause and Cardiovascular Survival in Dialysis Patients: Results from a Meta-Analysis. Kidney & blood pressure research, 2019, Volume: 44, Issue:6 Topics: Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Fractures, Bone; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Renal Dialysis; Survival Rate	2019
Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2020, Volume: 76, Issue:3 Topics: Adult; Calcimimetic Agents; Calcium; Cardiovascular Diseases; Cinacalcet; Comorbidity; Female; Fractures, Bone; Heart Failure; Humans; Hyperparathyroidism, Secondary; Male; Mortality; Naphthalenes; Nausea; Parathyroid Hormone; Peptides; Pyrrolidines; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome; Vomiting	2020
Vitamin D and Calcimimetics in Cardiovascular Disease. Seminars in nephrology, 2018, Volume: 38, Issue:3 Topics: Animals; Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Clinical Trials as Topic; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Renal Insufficiency; Vascular Calcification; Ventricular Remodeling; Vitamin D; Vitamin D Deficiency; Vitamins	2018
Mild primary hyperparathyroidism-to treat or not to treat? British medical bulletin, 2019, 03-01, Volume: 129, Issue:1 Topics: Bone Density; Calcium-Regulating Hormones and Agents; Cardiovascular Diseases; Cinacalcet; Clinical Decision-Making; Humans; Hyperparathyroidism, Primary; Neoplasms; Nephrolithiasis; Parathyroidectomy; Quality of Life	2019
Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS medicine, 2013, Volume: 10, Issue:4 Topics: Calcimimetic Agents; Calcium Metabolism Disorders; Cardiovascular Diseases; Cinacalcet; Humans; Hyperparathyroidism; Naphthalenes; Nausea; Parathyroid Hormone; Parathyroidectomy; Renal Insufficiency, Chronic; Vomiting	2013
Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism. Renal failure, 2014, Volume: 36, Issue:1 Topics: Bone Density; Cardiovascular Diseases; Cinacalcet; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Naphthalenes; Practice Guidelines as Topic	2014
What have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials? Current opinion in nephrology and hypertension, 2013, Volume: 22, Issue:6 Topics: Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic	2013
Dietary and pharmacological modification of fibroblast growth factor-23 in chronic kidney disease. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 2014, Volume: 24, Issue:3 Topics: Calcium; Calcium, Dietary; Cardiovascular Diseases; Chelating Agents; Cinacalcet; Diet; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Lanthanum; Naphthalenes; Phosphorus; Phosphorus, Dietary; Polyamines; Renal Insufficiency, Chronic; Sevelamer	2014
Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. The Cochrane database of systematic reviews, 2014, Issue:12 Topics: Calcimimetic Agents; Calcium; Cardiovascular Diseases; Cause of Death; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Phosphorus; Randomized Controlled Trials as Topic; Renal Dialysis	2014
[Vascular Calcification - Pathological Mechanism and Clinical Application - . The effect of cinacalcet on vascular calcification]. Clinical calcium, 2015, Volume: 25, Issue:5 Topics: Animals; Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Disease Progression; Humans; Naphthalenes; Randomized Controlled Trials as Topic; Receptors, Calcium-Sensing; Renal Insufficiency, Chronic; Vascular Calcification	2015
Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis. Clinical journal of the American Society of Nephrology : CJASN, 2016, Mar-07, Volume: 11, Issue:3 Topics: Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Research Design; Risk Factors; Treatment Outcome	2016
[Treatment for CKD-MBD(Chronic Kidney Disease-Mineral and Bone Disorder)]. Clinical calcium, 2016, Volume: 26, Issue:2 Topics: Bone and Bones; Bone Diseases, Metabolic; Calcimimetic Agents; Calcinosis; Calcium Carbonate; Cardiovascular Diseases; Cinacalcet; Ferric Compounds; Fractures, Bone; Humans; Minerals; Parathyroidectomy; Phosphates; Phosphorus, Dietary; Renal Insufficiency, Chronic; Risk Factors; Sevelamer	2016
Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis. Renal failure, 2016, Volume: 38, Issue:6 Topics: Calcimimetic Agents; Cardiovascular Diseases; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Fractures, Bone; Hospitalization; Humans; Parathyroid Hormone; Parathyroidectomy	2016
The new role of calcimimetics as vasculotropic agents. Kidney international, 2009, Volume: 75, Issue:1 Topics: Aniline Compounds; Calcinosis; Calcium; Cardiovascular Diseases; Cinacalcet; Humans; Naphthalenes; Phenethylamines; Propylamines; Receptors, Calcium-Sensing	2009
Cinacalcet: will it play a role in reducing cardiovascular events? Future cardiology, 2012, Volume: 8, Issue:3 Topics: Calcimimetic Agents; Cardiomyopathies; Cardiovascular Diseases; Cinacalcet; Disease Progression; Humans; Hyperparathyroidism, Secondary; Myocytes, Cardiac; Naphthalenes	2012
Fibroblast growth factor-23 helps explain the biphasic cardiovascular effects of vitamin D in chronic kidney disease. International journal of biological sciences, 2012, Volume: 8, Issue:5 Topics: Animals; Calcimimetic Agents; Cardiovascular Diseases; Chelating Agents; Cinacalcet; Diet; Endothelium, Vascular; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Hypertrophy, Left Ventricular; Kidney Failure, Chronic; Kidney Transplantation; Male; Naphthalenes; Parathyroid Hormone; Phosphates; Polyamines; Renal Insufficiency, Chronic; Sevelamer; Vascular Calcification; Vitamin D; Vitamin D Deficiency	2012
Regression of vascular calcification in chronic kidney disease - feasible or fantasy? a review of the clinical evidence. British journal of clinical pharmacology, 2013, Volume: 76, Issue:4 Topics: Animals; Calcium; Cardiovascular Diseases; Cinacalcet; Humans; Naphthalenes; Phosphates; Primary Prevention; Renal Dialysis; Renal Insufficiency, Chronic; Secondary Prevention; Vascular Calcification	2013
[Cinacalcet therapy and cardiovascular risk in hemodialysis patients]. Postepy higieny i medycyny doswiadczalnej (Online), 2012, Oct-22, Volume: 66 Topics: Atherosclerosis; Cardiovascular Diseases; Causality; Cinacalcet; Comorbidity; Disease Progression; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Renal Dialysis; Risk Factors; Vascular Calcification	2012
Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney international, 2005, Volume: 68, Issue:4 Topics: Adult; Aged; Cardiovascular Diseases; Cinacalcet; Female; Fractures, Bone; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Quality of Life; Randomized Controlled Trials as Topic; Risk Factors	2005
[Chronic kidney disease]. Medizinische Klinik (Munich, Germany : 1983), 2005, Nov-15, Volume: 100, Issue:11 Topics: Acidosis; Adult; Anemia, Aplastic; Cardiovascular Diseases; Cinacalcet; Disease Progression; Glomerular Filtration Rate; Humans; Hyperparathyroidism, Secondary; Hypertension; Kidney Failure, Chronic; Kidney Transplantation; Multicenter Studies as Topic; Naphthalenes; Parathyroid Hormone; Practice Guidelines as Topic; Risk Factors	2005
The diagnosis and management of asymptomatic primary hyperparathyroidism. Nature clinical practice. Endocrinology & metabolism, 2006, Volume: 2, Issue:9 Topics: Bone Diseases; Cardiovascular Diseases; Cinacalcet; Diphosphonates; Estrogens; Gastrointestinal Diseases; Humans; Hypercalcemia; Hyperparathyroidism, Primary; Naphthalenes; Parathyroid Glands; Phosphates; Renal Insufficiency	2006
The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation. Health technology assessment (Winchester, England), 2007, Volume: 11, Issue:18 Topics: Cardiovascular Diseases; Cinacalcet; Cost-Benefit Analysis; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Markov Chains; Middle Aged; Models, Economic; Naphthalenes; Parathyroid Hormone; Phosphates; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptors, Calcium-Sensing; Renal Dialysis; Vitamin D	2007
Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. Journal of managed care pharmacy : JMCP, 2007, Volume: 13, Issue:5 Topics: Calcitriol; Cardiovascular Diseases; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Cost-Benefit Analysis; Drug Costs; Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Parathyroid Hormone; Parathyroidectomy; Renal Insufficiency, Chronic; Vitamin D; Vitamins	2007
CKD-MBD: impact on management of kidney disease. Clinical and experimental nephrology, 2007, Volume: 11, Issue:4 Topics: Aniline Compounds; Bone Diseases, Metabolic; Calcium Metabolism Disorders; Cardiovascular Diseases; Chelating Agents; Cinacalcet; Disease Progression; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Lanthanum; Naphthalenes; Phenethylamines; Polyamines; Propylamines; Renal Insufficiency, Chronic; Sevelamer; Vitamin D; Vitamin D Deficiency; Vitamins	2007

Trials

11 trial(s) available for cinacalcet and Cardiovascular Diseases

Article	Year
Angiotensin-related genetic determinants of cardiovascular disease in patients undergoing hemodialysis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2019, 11-01, Volume: 34, Issue:11 Topics: Angiotensins; Cardiovascular Diseases; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Meta-Analysis as Topic; Middle Aged; Peptidyl-Dipeptidase A; Polymorphism, Single Nucleotide; Prognosis; Receptor, Angiotensin, Type 1; Renal Dialysis; Survival Rate	2019
A randomized controlled trial of different serum phosphate ranges in subjects on hemodialysis. BMC nephrology, 2019, 02-04, Volume: 20, Issue:1 Topics: Aged; Cardiovascular Diseases; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Female; Follow-Up Studies; Humans; Hydroxycholecalciferols; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Patient Acceptance of Health Care; Patient Dropouts; Phosphates; Phosphorus, Dietary; Renal Dialysis; Sepsis; Sevelamer	2019
The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Clinical journal of the American Society of Nephrology : CJASN, 2015, May-07, Volume: 10, Issue:5 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Parathyroidectomy; Renal Dialysis; Severity of Illness Index	2015
The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial. Journal of human hypertension, 2016, Volume: 30, Issue:3 Topics: Adult; Aged; Blood Pressure; Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Female; Humans; Male; Middle Aged; Vascular Stiffness	2016
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Circulation, 2015, Jul-07, Volume: 132, Issue:1 Topics: Adult; Aged; Cardiovascular Diseases; Cinacalcet; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperthyroidism; Male; Middle Aged; Naphthalenes; Renal Dialysis	2015
Analyzing Health-Related Quality of Life in the EVOLVE Trial: The Joint Impact of Treatment and Clinical Events. Medical decision making : an international journal of the Society for Medical Decision Making, 2016, Volume: 36, Issue:8 Topics: Adult; Aged; Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Cost-Benefit Analysis; Double-Blind Method; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Quality of Life; Quality-Adjusted Life Years; Regression Analysis; Renal Dialysis; Research Design	2016
Blood Calcification Propensity, Cardiovascular Events, and Survival in Patients Receiving Hemodialysis in the EVOLVE Trial. Clinical journal of the American Society of Nephrology : CJASN, 2017, 02-07, Volume: 12, Issue:2 Topics: Adult; Aged; Angina, Unstable; Calcimimetic Agents; Calcinosis; Cardiovascular Diseases; Cause of Death; Cinacalcet; Female; Heart Failure; Hematologic Tests; Hospitalization; Humans; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Infarction; Peripheral Vascular Diseases; Predictive Value of Tests; Prospective Studies; Renal Dialysis; Survival Rate	2017
Secondary hyperparathyroidism in chronic dialysis patients: results of the Italian FARO survey on treatment and mortality. Blood purification, 2011, Volume: 32, Issue:2 Topics: Aged; Calcitriol; Cardiovascular Diseases; Cinacalcet; Ergocalciferols; Female; Humans; Hyperparathyroidism, Secondary; Italy; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Odds Ratio; Prospective Studies; Renal Dialysis; Risk Factors; Survival Rate; Vitamins	2011
Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2012, Volume: 27, Issue:7 Topics: Australia; Bone Diseases; Calcimimetic Agents; Canada; Cardiovascular Diseases; Cinacalcet; Double-Blind Method; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Minerals; Naphthalenes; Prognosis; Renal Dialysis; Russia; Survival Rate; United States; Vitamin D	2012
A pilot study of active vitamin D administration and insulin resistance in African American patients undergoing chronic hemodialysis. Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 2013, Volume: 23, Issue:3 Topics: Absorptiometry, Photon; Adipokines; Biomarkers; Black or African American; Body Composition; Cardiovascular Diseases; Chronic Disease; Cinacalcet; Double-Blind Method; Endpoint Determination; Female; Glucose Clamp Technique; Humans; Hyperinsulinism; Inflammation; Insulin Resistance; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Pilot Projects; Receptors, Calcium-Sensing; Renal Dialysis; Risk Factors; Vitamin D; Vitamin D Deficiency	2013
Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. The New England journal of medicine, 2012, Dec-27, Volume: 367, Issue:26 Topics: Adult; Aged; Cardiovascular Diseases; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Hypocalcemia; Intention to Treat Analysis; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Odds Ratio; Parathyroid Hormone; Renal Dialysis	2012

Other Studies

18 other study(ies) available for cinacalcet and Cardiovascular Diseases

Article	Year
Serum testosterone concentrations and outcomes in hemodialysis patients enrolled in the EVOLVE trial. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2023, 05-31, Volume: 38, Issue:6 Topics: Cardiovascular Diseases; Cinacalcet; Female; Humans; Male; Renal Dialysis; Testosterone	2023
PTH control and cardiovascular outcomes: does the treatment approach matter? Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2023, 07-31, Volume: 38, Issue:8 Topics: Cardiovascular Diseases; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Parathyroidectomy; Peritoneal Dialysis	2023
Surgery for Renal Hyperparathyroidism in the Era of Cinacalcet: A Single-Center Experience. Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society, 2021, Volume: 110, Issue:1 Topics: Biomarkers; Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Female; Humans; Hyperparathyroidism; Kidney Transplantation; Male; Middle Aged; Parathyroidectomy; Postoperative Complications; Retrospective Studies	2021
Mortality in dialysis patients with cinacalcet use: A large observational registry study. European journal of internal medicine, 2017, Volume: 42 Topics: Adolescent; Adult; Aged; Austria; Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Parathyroid Hormone; Registries; Renal Dialysis; Retrospective Studies; Survival Analysis; Vitamin D; Young Adult	2017
Prospective cohort study: Cinacalcet-mediated lowering of PTH level and cardiovascular disease mortality in younger Korean patients with stage 5 CKD at a Korean secondary hospital. Journal of clinical pharmacy and therapeutics, 2017, Volume: 42, Issue:5 Topics: Adolescent; Adult; Age Factors; Aged; Asian People; Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Cohort Studies; Female; Glomerular Filtration Rate; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Parathyroid Hormone; Prospective Studies; Renal Insufficiency, Chronic; Republic of Korea; Young Adult	2017
Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism. Scientific reports, 2018, 02-01, Volume: 8, Issue:1 Topics: Aged; Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Female; Fractures, Bone; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Sweden	2018
Trimethylamine Clinical journal of the American Society of Nephrology : CJASN, 2019, 02-07, Volume: 14, Issue:2 Topics: Adult; Aged; Angina, Unstable; Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Female; Hospitalization; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Methylamines; Middle Aged; Mortality; Myocardial Infarction; Randomized Controlled Trials as Topic; Renal Dialysis; Stroke	2019
[EVOLVE: between disappointment and optimism]. Nephrologie & therapeutique, 2013, Volume: 9, Issue:4 Topics: Cardiovascular Diseases; Cinacalcet; Hospitalization; Humans; Naphthalenes; Renal Dialysis; Treatment Outcome	2013
The EVOLVE study is negative, so what does this 'bitter pill' of disappointment mean now for renal patients? International journal of clinical practice, 2014, Volume: 68, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Humans; Hyperparathyroidism; Middle Aged; Multicenter Studies as Topic; Naphthalenes; Parathyroid Hormone; Prospective Studies; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Renal Replacement Therapy; Treatment Outcome; Young Adult	2014
Impact of pre-transplant antiaggregant and anticoagulant therapies on early hemorrhagic and cardiovascular events after kidney transplantation. Journal of nephrology, 2015, Volume: 28, Issue:6 Topics: Adult; Anticoagulants; Blood Transfusion; Cardiovascular Diseases; Cinacalcet; Delayed Graft Function; Female; Humans; Kidney Transplantation; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Postoperative Period; Preoperative Care; Retrospective Studies; Risk Factors; Time Factors; Vitamin K	2015
Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial. Hemodialysis international. International Symposium on Home Hemodialysis, 2016, Volume: 20, Issue:3 Topics: Cardiovascular Diseases; Cinacalcet; Dialysis Solutions; Female; Humans; Male; Middle Aged; Renal Dialysis	2016
Optimal TARGETs for cardiovascular safety and benefit in ESRD. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2008, Volume: 23, Issue:10 Topics: Calcium; Cardiovascular Diseases; Cinacalcet; Drug Therapy, Combination; Humans; Hyperparathyroidism, Secondary; Hypocalcemia; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Safety; Sterols; Vitamin D	2008
Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney international, 2010, Volume: 78, Issue:6 Topics: Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Cohort Studies; Databases, Factual; Drug Evaluation; Humans; Kidney Failure, Chronic; Naphthalenes; Prospective Studies; Renal Dialysis; Survival Rate; Vitamin D	2010
Lead-time bias in studies of cinacalcet prescriptions. Kidney international, 2010, Volume: 78, Issue:6 Topics: Bias; Cardiovascular Diseases; Cause of Death; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Observation; Treatment Outcome	2010
Cinacalcet and cardiovascular mortality in hemodialysis patients. Kidney international, 2010, Volume: 78, Issue:8 Topics: Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Humans; Naphthalenes; Receptors, Calcium-Sensing; Renal Dialysis; Renal Insufficiency, Chronic	2010
Multidisciplinary treatment. A therapeutic option to treat calciphylaxis. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2011, Volume: 31, Issue:5 Topics: Anti-Bacterial Agents; Antiphospholipid Syndrome; Calciphylaxis; Carcinoma, Renal Cell; Cardiovascular Diseases; Cinacalcet; Clostridium Infections; Clostridium perfringens; Combined Modality Therapy; Debridement; Foot Ulcer; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Kidney Neoplasms; Kidney Transplantation; Male; Middle Aged; Naphthalenes; Postoperative Complications; Renal Replacement Therapy; Staphylococcal Infections; Thiosulfates	2011
Trials in kidney disease--time to EVOLVE. The New England journal of medicine, 2012, Dec-27, Volume: 367, Issue:26 Topics: Cardiovascular Diseases; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Naphthalenes; Renal Dialysis	2012
Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clinical journal of the American Society of Nephrology : CJASN, 2007, Volume: 2, Issue:5 Topics: Cardiovascular Diseases; Cinacalcet; Double-Blind Method; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Randomized Controlled Trials as Topic; Renal Dialysis	2007